Age-related macular degeneration (AMD) is a leading cause of blindness in people over the age of 50, and neovascular AMD, also known as wet AMD, is a particularly severe form of the disease. Preclinical animal models play a crucial role in understanding the disease pathology, testing novel therapies, and translating the findings to clinical trials. At MediNect Bioservices, we specialize in preclinical research for neovascular AMD, and we have a range of well-established models designed to mimic the key features of human nAMD that allow us to study the efficacy of potential therapeutics.